Travere Therapeutics (TVTX) Return on Equity: 2013-2025
Historic Return on Equity for Travere Therapeutics (TVTX) over the last 11 years, with Sep 2025 value amounting to -0.53%.
- Travere Therapeutics' Return on Equity fell 86.00% to -0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.53%, marking a year-over-year decrease of 86.00%. This contributed to the annual value of -0.01% for FY2024, which is 218.00% down from last year.
- As of Q3 2025, Travere Therapeutics' Return on Equity stood at -0.53%, which was up 67.76% from -1.65% recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' Return on Equity registered a high of 5.32% during Q2 2024, and its lowest value of -1.65% during Q2 2025.
- In the last 3 years, Travere Therapeutics' Return on Equity had a median value of 0.40% in 2023 and averaged 0.71%.
- In the last 5 years, Travere Therapeutics' Return on Equity spiked by 493bps in 2024 and then plummeted by 697bps in 2025.
- Over the past 5 years, Travere Therapeutics' Return on Equity (Quarterly) stood at -0.71% in 2021, then surged by 145bps to 0.74% in 2022, then soared by 36bps to 1.10% in 2023, then tumbled by 117bps to -0.07% in 2024, then plummeted by 86bps to -0.53% in 2025.
- Its Return on Equity was -0.53% in Q3 2025, compared to -1.65% in Q2 2025 and -0.92% in Q1 2025.